What's Happening?
AbbVie (ABBV) has announced primary Phase 2a results for ABBV-466, an investigational two-drug combination therapy for Crohn's disease. The data, presented at a gastroenterology meeting in Barcelona on October 19, indicated that the combination therapy achieved
endoscopic remission in 40.5% of patients by Week 24, significantly outperforming Skyrizi alone, which showed a 22.4% remission rate. This outcome is close to the 'doubling' of endoscopic remission previously cited by Head of R&D and Chief Scientific Officer Roopal Thakkar. The study is open-label and ongoing, involving 300 patients, with 75% having previously failed at least one advanced therapy. Serious adverse events were comparable between the combination (10.4%) and Skyrizi alone (9.6%). Despite the positive clinical data, AbbVie's shares experienced a slight dip of 0.96% on the day of the announcement, closing at $282.68. The company is also awaiting FDA approval for subcutaneous Skyrizi induction for Crohn's, which was still under review as of October 13.
Why It's Important?
This development is significant for AbbVie as it seeks to bolster its immunology portfolio and mitigate the impact of Humira's patent expiration. The success of ABBV-466 in Phase 2a suggests a potential future treatment option that could offer superior efficacy for Crohn's disease patients, particularly those who have not responded to existing advanced therapies. If further trials confirm these results, the combination therapy could become a major revenue driver for AbbVie in the 2030s, as projected by Chief Commercial Officer Jeff Stewart. The company has already demonstrated its ability to offset Humira's revenue erosion with growth from Skyrizi and Rinvoq, which collectively surpassed Humira's peak sales. A new, highly effective treatment for Crohn's would further solidify AbbVie's market position in immunology and contribute to its long-term growth strategy, potentially attracting new patients and retaining existing ones within its therapeutic ecosystem.
What's Next?
AbbVie plans to proceed with a Phase IIb trial for ABBV-466, which will test a higher dose of the α4β7 drug component. The company also aims to co-formulate and deliver the two drugs in a single injection, simplifying administration for patients. Commercial availability of this combination therapy is anticipated in the early 2030s. In the more immediate future, AbbVie is awaiting FDA approval for subcutaneous Skyrizi induction for Crohn's disease, which is expected in the fourth quarter. The company is also scheduled to release its third-quarter results before the market opens on October 30. These upcoming events, particularly the FDA decision and earnings report, will be closely watched by investors and could influence the stock's short-term performance. Analyst expectations for AbbVie's adjusted EPS for the third quarter are around $3.79, with a range of $3.73 to $3.77.
Beyond the Headlines
The development of ABBV-466 highlights a broader trend in pharmaceutical research towards combination therapies to address complex diseases like Crohn's, where single-agent treatments may not achieve optimal outcomes for all patients. By targeting multiple pathways involved in the disease's pathology, combination drugs aim to improve efficacy and potentially overcome resistance mechanisms. This approach could set a new standard of care in gastroenterology, offering patients more robust and sustained remission. Furthermore, the focus on developing a co-formulated single injection underscores the industry's drive towards enhancing patient convenience and adherence, which are critical factors in the long-term management of chronic conditions. The success of such complex drug development programs also reinforces the importance of sustained R&D investment in the biopharmaceutical sector, driving innovation that can significantly improve patient quality of life and create substantial economic value.
